AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

# THE RELEVANCE OF MEDICINES USED FOR HEART FAILURE AND MEASURES TO IMPROVE THEM

**Sokhib Rashidov Zamon o'g'li**
**Davronbek A'zamov Salim o'g'li**
**Zukhriddin O‘rishboev Alisher o‘g‘li**
Department of the pharmacology of the Tashkent state medical university

**Abstract.** Heart failure affects millions of people globally and is a significant and growing global health concern. Numerous etiologies, including ischemic heart disease, hypertension, valve anomalies, and cardiomyopathies, can cause this complex condition. The incapacity of the heart to pump blood effectively enough to meet the body's metabolic needs is known as heart failure, and it causes debilitating symptoms, frequent hospital stays, and high death rates. Heart failure has traditionally been treated with an emphasis on improving cardiac contractility, decreasing fluid retention, and symptom relief. These objectives have been accomplished via a combination of device-based interventions, such as implanted cardioverter-defibrillators and cardiac resynchronization therapy, and pharmaceutical therapies, such as beta-blockers, diuretics, and angiotensin-converting enzyme inhibitors. The unrelenting progression of heart failure, however, continues to be a major clinical concern in spite of recent advancements. Among the complex mechanisms influencing the disease's development are cellular remodeling, cardiac fibrosis, and neurohormonal activation. Researchers and medical professionals have been searching for new therapeutic strategies that target these basic systems in recent years. One such area of research is the cutting-edge field of gene therapy, where promising gene-editing methods like CRISPR-Cas9 may provide ways to fix genetic abnormalities that cause heart failure. Furthermore, there is great potential for rebuilding damaged heart tissue and regaining function through regenerative medicine techniques including tissue engineering and stem cell therapy. Additionally, efforts in precision medicine have gained momentum with the goal of customizing heart failure treatments to each patient's unique profile while accounting for comorbidities, biomarkers, and genetics. Predictive models for early intervention, risk assessment, and individualized therapy recommendations have also been made possible by the integration of AI and machine learning in the management of heart failure. By focusing on the disease's underlying mechanisms, these novel treatments for heart failure have the potential to completely transform the sector, as this narrative review highlights. By investigating these cutting-edge strategies, we seek to offer a thorough understanding of the changing paradigm of heart failure treatment, encouraging optimism in both patients and medical professionals.

**Keywords.** heart failure, cardiac care, thorough evaluation, new treatments, developments, management.

**Introduction.** Heart failure is a fast expanding worldwide health concern that has a substantial influence on people and healthcare systems everywhere. The sickness in question is distinguished by its complexity and diversity, which significantly impairs the general well-being of those afflicted and places a heavy financial burden on them. The important topic of "Advancements in Heart Failure Management," with a focus on creating treatments that could have a big influence on the area of heart failure care, is examined in this narrative review. The important topic of "Advancements in Heart Failure Management," with a focus on creating treatments that could have a big influence on the area of heart failure care, is examined in this

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

narrative review. This narrative review is important not just because it critically evaluates new treatment approaches but also because it recognizes heart failure as a serious public health issue that requires creative solutions [1-6]. Understanding the scope and seriousness of the problem is essential to appreciating the significance of advancements in the treatment of heart failure. About 64 million people worldwide suffer from heart failure, which has a major impact on many people. Furthermore, this illness is becoming more and more common. The aging population and a larger prevalence of cardiovascular risk factors like obesity, diabetes, and hypertension can be largely attributed to the rise in heart failure cases. Since heart failure-related medical expenses amount to billions of dollars annually, the ailment has a substantial financial impact. Apart from its monetary consequences, heart failure severely impairs the general health of those who suffer from it. This is demonstrated by the onset of symptoms like dyspnea, or difficulty breathing, weariness, or a decreased capacity to exercise (exercise intolerance). In the end, these symptoms lead to a significant reduction in life expectancy. Recent decades have seen a significant evolution in heart failure treatment, mostly due to improvements in clinical procedures and research [7-11]. Historically, the mainstay of treating heart failure has been pharmacological treatments, including beta-blockers, angiotensin receptor blockers (ARBs), diuretics, and angiotensin-converting enzyme (ACE) inhibitors. These medications' main goals are to improve cardiac function, reduce fluid retention, and lessen symptoms. Furthermore, implantable devices like cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs) have become essential tools in the fight against heart failure, showing notable decreases in hospitalizations and mortality among particular patient populations. For patients with end-stage heart failure, heart transplantation has long been the recommended course of treatment. It provides a critical opportunity for those with ongoing symptoms and impaired cardiac function. However, its potential adoption is hampered by the scarcity of donor organs. Despite these significant improvements in treatment, heart failure still presents significant challenges [12-19]. Despite the availability of modern medications, it is important to recognize that not all patients respond well to treatment, and the illness often progresses steadily. Adverse effects, pharmaceutical intolerances, and non-adherence to intricate prescription regimens can all make managing medical illnesses more difficult. Alternative and complementary therapies for heart failure treatment are desperately needed. The need for new therapeutic approaches is essential given the ongoing rise in the prevalence of heart failure and the limitations of current therapies. Advanced pharmaceutical agents, device-based interventions, regenerative medicine initiatives, and precision medicine studies are just a few of the creative approaches that make up emerging therapeutics. Improving patient outcomes, maximizing quality of life, and more effectively addressing the underlying mechanisms of heart failure are the main goals of these emerging medications. This narrative review looks closely at these new medications and how they might revolutionize the way heart failure is treated [20-27]. This study looks closely at recent developments and their possible effects in an effort to add to the body of knowledge already available on heart failure. The ultimate objective is to promote advancement and creativity in the field. The objective of this research is to do a comprehensive analysis of the various emerging medications used to treat heart failure, looking at their underlying mechanisms of action, clinical effectiveness, and potential advantages over current treatment approaches. Every emerging treatment will go through a thorough study to determine its benefits and inherent limitations. A thorough analysis of these therapeutic modalities will provide researchers and doctors with important information to help them make well-informed decisions about incorporating them into clinical practice. The narrative review will conclude by suggesting potential directions for further research and development in the treatment of heart failure. Finding subjects that require more

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

investigation can be a useful strategy for directing upcoming studies and encouraging a continuous innovation culture. In order to give a comprehensive analysis of the innovations that have the potential to revolutionize the treatment of this pervasive worldwide health concern, this narrative review will examine the wide variety of emerging therapies for heart failure [28-39].

**The main purpose** of the presented manuscript is to summarize the results of reputable scientific papers on medicines used in heart failure and the relevance of measures to improve them.

**Heart failure epidemiology.** Millions of individuals worldwide suffer from heart failure, a widespread health issue. Due to aging populations, better heart attack survival rates, and a growing load of risk factors like obesity, diabetes, and hypertension, its incidence is still rising. An estimated 6.2 million persons in the United States who were 20 years of age or older suffered from heart failure in 2019. There is a significant mortality and morbidity burden linked to heart failure. The severity, underlying cause, and availability of medical care all affect the prognosis. Advanced heart failure can have a five-year mortality rate of over 50%, whereas the one-year mortality rate after diagnosis can be between 20% and 30%. Furthermore, heart failure is one of the main reasons older persons are admitted to hospitals, placing a heavy financial strain on healthcare systems. Heart failure has a significant economic impact. Recurrent hospitalizations, costly procedures, and long-term care put a significant financial burden on healthcare systems. In 2012, the estimated direct and indirect expenses of heart failure in the United States alone exceeded $30 billion [6-14].

**Heart failure classification.** Heart failure with preserved ejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF). A left ventricular ejection fraction (LVEF) of less than 40% is indicative of HFrEF. It is more frequently linked to disorders such ischemic heart disease, cardiomyopathies, or myocarditis and is frequently linked to compromised heart muscle contractile performance. Patients with HFpEF have an LVEF that is much higher than 50%. HFpEF, which frequently occurs in the setting of diabetes, hypertension, or age, is linked to decreased relaxation and increased left ventricular stiffness [1-5]. The European Society of Cardiology created a third category called heart failure with mid-range ejection fraction (HFmrEF) in recognition of the shortcomings of the HFrEF and HFpEF classifications. This group attempts to address the variable nature of heart failure and includes patients with LVEF between 40% and 49%. This type frequently requires prompt medical intervention since it manifests suddenly. It is usually characterized by a quick onset of symptoms, which might result in abrupt decompensation and necessitate hospitalization. The symptoms of chronic heart failure are long-lasting and persistent. To reduce symptoms and enhance the patient's quality of life, it requires continuous medical care [12-17].

**Heart failure is multifactorial.** Heart failure is the last common pathway of several cardiac and non-cardiac disorders rather than a single disease entity. Both diagnosis and treatment are complicated due to its multifaceted character. Heart failure, especially HFrEF, is largely caused by myocardial infarction, persistent ischemia, and coronary artery disease. Heart failure can result from restrictive, hypertrophic, and dilated cardiomyopathy. Heart failure can develop as a result of conditions like mitral regurgitation and aortic stenosis that overwhelm the heart. cardiac failure can result from severe and poorly managed arrhythmias that interfere with regular cardiac function. HFpEF can be exacerbated by chronic hypertension, which can cause diastolic dysfunction and left ventricular hypertrophy. A higher risk of heart failure is linked to uncontrolled diabetes, potentially as a result of both macrovascular and microvascular alterations [21-28]. Due to its role in systolic and diastolic dysfunction, obesity is a major risk factor for heart failure. Heart failure and chronic renal disease frequently have a reciprocal relationship in

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

which each illness exacerbates the other. Heart failure can result from the right ventricle being strained by pulmonary hypertension and chronic obstructive pulmonary disease (COPD). Severe anemia can lower the body's ability to carry oxygen, which puts more stress on the heart. Heart failure can result from myocardial injury caused by illicit drug use, excessive alcohol use, and exposure to cardiotoxic drugs. Heart failure also has a hereditary component. An individual's risk of heart failure might be increased by genetic abnormalities and familial predispositions, especially in cardiomyopathies [30-35].

**Pharmacological treatments.** One of the mainstays of treatment for HFrEF has been ACE inhibitors. They inhibited the synthesis of aldosterone and angiotensin II, a strong vasoconstrictor, which resulted in vasodilation and less water and salt retention. Enalapril, lisinopril, and ramipril are important medications in this class. Enalapril significantly reduced mortality in individuals with severe heart failure, as shown by the historic CONSENSUS trial. For patients who are intolerant to ACE inhibitors, ARBs like losartan and valsartan provide an alternative. They have demonstrated efficacy in lowering morbidity and mortality in individuals with heart failure by blocking the activity of angiotensin II at the receptor level. Carvedilol, metoprolol, and bisoprolol are examples of beta-blockers that have become an essential treatment choice for HFrEF [13-19]. By counteracting the effects of catecholamines, these medications improve contractility while lowering heart rate and myocardial oxygen consumption. The effectiveness of bisoprolol in lowering mortality in individuals with HFrEF was shown by the CIBIS-II trial. By targeting aldosterone receptors, mineralocorticoid receptor antagonists (MRAs) like eplerenone and spironolactone reverse the sodium and water-retaining effects of aldosterone. The advantages of spironolactone in lowering mortality in patients with severe HFrEF were demonstrated by the RALES trial. A novel treatment for HFrEF is sacubitril/valsartan, a combination of an ARB (valsartan) and a neprilysin inhibitor (sacubitril). It increases natriuretic peptide levels while preventing angiotensin II's negative effects. Sacubitril/valsartan outperformed enalapril in the PARADIGM-HF trial in terms of lowering heart failure hospitalizations and cardiovascular death [21-28]. Furosemide and hydrochlorothiazide are examples of diuretics that are crucial for controlling fluid overload in heart failure. They encourage diuresis, which reduces congestion symptoms. However, prolonged use of these can result in renal impairment and electrolyte abnormalities. Digoxin is still a possibility in some heart failure instances, especially for atrial fibrillation patients' rate control. Although it can alleviate symptoms and has beneficial inotropic effects, mortality is not greatly affected. A heart rate-lowering drug called ivabradine is prescribed to HFrEF patients who continue to experience symptoms even after receiving the best possible medical care. It lowers heart rate without having negative inotropic effects by blocking the funny current (If) in the sinoatrial node [29-39].

**Clinical Consequences.** There are numerous important clinical ramifications when incorporating new treatments into the clinical treatment of heart failure. Treatment strategies can now be customized to each patient's unique profile thanks to emerging medicines. Medical professionals can choose the best treatments and track their efficacy by using clinical data, biomarkers, and genetic information. This customized strategy can enhance results and lower the possibility of unfavorable occurrences. More precise risk assessment and early intervention are made possible by precision medicine, which is made possible by new treatments. Healthcare professionals can proactively modify treatment plans and lifestyle advice to avoid difficulties by identifying patients who are more likely to experience heart failure exacerbations or other negative outcomes. Novel medications and stem cell-based therapies are examples of emerging medicines that have the potential for focused interventions that target the underlying causes of

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

heart failure. We can anticipate the creation of more accurate and successful therapies as our knowledge of the disease's molecular causes grows [11-21]. Clinical decision-making based on data, aided by AI and machine learning, is becoming more and more significant. Large datasets can be analyzed by these technologies to find trends, forecast results, and help medical professionals make well-informed decisions about patient care. A multidisciplinary approach to patient care is required when integrating precision medicine with new medicines. Cardiologists, genetic counselors, pharmacists, and other experts may work together in heart failure teams to provide thorough, customized care. Precision medicine and new treatments depend heavily on patient empowerment and engagement. Better results can be achieved when patients actively participate in their care and make informed decisions that reflect their values and preferences. The management of heart failure is a dynamic and ever-changing profession. In order to enhance patient care, research and development initiatives will probably improve current treatments, find new targets, and investigate novel strategies. Innovation will be fueled by cooperation between researchers, physicians, and business partners [30-36].

**Future Directions.** A number of future directions and areas of research and development might be envisaged as new medicines continue to emerge. Large datasets can be analyzed by AI and machine learning systems to find intricate patterns and forecast patient outcomes. These technologies have the potential to improve risk prediction models and inform treatment choices. A key component of precision medicine is giving patients the tools they need to actively engage in their care. Shared decision-making can be improved and treatment decisions can be informed by patient-reported outcomes and preferences. A more thorough understanding of a person's health can be obtained by incorporating proteomics, metabolomics, genomics, and other omics data into therapeutic practice. These data sources may provide new therapeutic targets and biomarkers. The development of targeted medicines that target particular disease subtypes may result from advances in our understanding of the molecular mechanisms underlying heart failure. These treatments can be customized to fit the unique characteristics of each patient. Real-world data is required to evaluate the long-term safety and efficacy of novel treatments, even while clinical studies offer insightful information [5-13]. Comparative efficacy studies, patient registries, and post-marketing surveillance all help to shed light on how well these treatments work in actual clinical settings. Cost-effectiveness studies will become increasingly important as the use of new medicines grows. Resource allocation and reimbursement decisions will be influenced by assessing the economic impact of these treatments in actual healthcare systems. Future studies could examine the advantages of integrating cutting-edge therapy with well-established ones. In the treatment of heart failure, pharmaceutical advancements, device-based therapies, and regenerative medicine may work in concert. The goal of further research will probably be to identify new biomarkers linked to heart failure. These biomarkers may enhance risk assessment, diagnosis, and therapy recommendations. New avenues for altering the genetic foundations of heart failure may become possible with the development of gene editing tools such as CRISPR-Cas9. Innovative gene therapies may result from research in this field. Modifications to healthcare delivery models may be required in order to incorporate developing medicines. Precision medicine delivery can be improved by research on telehealth applications, patient navigation systems, and care pathway optimization [19-27].

**Discussion.** The prevalence of heart failure. Millions of individuals worldwide suffer from heart failure, which is a widespread health issue. Due to aging populations, increased survival rates after heart attacks, and a growing load of risk factors like obesity, diabetes, and hypertension, its incidence is still rising. Heart failure was expected to affect 6.2 million persons in the United States who were 20 years of age or older in 2019. A significant burden of death and

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

morbidity is linked to heart failure. The severity, underlying cause, and access to medical care all affect the prognosis. While the five-year mortality rate for severe heart failure can surpass 50%, the one-year mortality rate after diagnosis can vary between 20% and 30%. A significant and growing global health concern, heart failure affects millions of people worldwide. This complicated illness has a variety of causes, including cardiomyopathies, hypertension, valve anomalies, and ischemic heart disease. Debilitating symptoms, frequent hospitalizations, and high death rates are brought on by the heart's incapacity to pump blood effectively enough to meet the body's metabolic demands. Reducing fluid retention, improving cardiac contractility, and easing symptoms have historically been the main goals of heart failure treatment [3-9]. Pharmacological treatments including beta-blockers, angiotensin-converting enzyme inhibitors, and diuretics, together with device-based interventions like implanted cardioverter-defibrillators and cardiac resynchronization therapy, have been used to accomplish these goals. Nevertheless, heart failure's unrelenting progression continues to be a major therapeutic concern in spite of these advancements. Cellular remodeling, cardiac fibrosis, and neurohormonal activation are a few of the many mechanisms driving the disease's advancement. In recent years, scientists and medical professionals have set out to find new therapy strategies that target these basic systems. The cutting-edge science of gene therapy is one such line of inquiry. Promising gene-editing methods, such CRISPR-Cas9, provide possible ways to fix genetic abnormalities that lead to heart failure. Furthermore, methods of regenerative medicine, such as tissue engineering and stem cell therapy, have great potential to repair damaged heart tissue and restore function. Precision medicine and new medicines depend heavily on patient empowerment and engagement [14-21]. With the potential to significantly influence patient care, clinical decision-making, and the overall field of heart failure management, emerging therapeutics for the treatment of heart failure show great promise. The therapeutic implications of these treatments are explored, along with potential avenues for future research and development. Patients who actively engage in their care and are well-informed are able to make choices that are consistent with their values and preferences, which eventually improves results. The management of heart failure is an ever-changing and dynamic field. In order to enhance patient care, research and development initiatives will probably improve current treatments, find new targets, and investigate cutting-edge strategies. Innovation will be fueled by cooperation between researchers, medical professionals, and business partners. Additionally, efforts to customize heart failure treatments to each patient's unique profile while accounting for comorbidities, biomarkers, and genetics have gained momentum. Predictive models for early intervention, risk stratification, and individualized therapy recommendations have also been made possible by the integration of AI and machine learning in heart failure management [25-32]. This narrative review traverses the complex terrain of new heart failure treatments, highlighting their potential to transform the field by focusing on the underlying causes of the illness. We intend to offer a thorough understanding of the changing paradigm of heart failure care by investigating these cutting-edge strategies, giving both patients and doctors cause for optimism [33-39].

**Conclusion.** In summary, this review has examined the complexities, difficulties, and exciting advancements in the management of heart failure, highlighting its multiple nature. The main conclusions highlight the revolutionary potential of continuous improvements in the treatment of heart failure. From cutting-edge pharmaceutical treatments to cutting-edge device-based therapies, regenerative medicine, and precision care, these advancements give patients dealing with this difficult condition hope. Customized treatment regimens, accurate risk assessment, and a move toward more patient-centered care are made possible by these developments.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

For those with heart failure, the combination of multidisciplinary teamwork, patient empowerment, and data-driven clinical decision-making promises better results and a higher quality of life. It is evident that the search for new treatments and precision medicine in the treatment of heart failure is not only a scientific undertaking but also a moral one as we negotiate the difficulties of cost, accessibility, and ethical issues. The way heart failure is treated in the future has the potential to improve patient outcomes, lessen inequities, and even save lives. We may anticipate a better future for heart failure patients and a completely transformed care environment with continued research and commitment.

**References.**

1. Lin Q, Lv Z, Li D, Ling Q, Qiu S, Lei X, Qin F, Wang N. Heart failure medication treatment and prognosis: a retrospective cross-sectional study. Front Pharmacol. 2025 Jun 12;16:1532123. doi: 10.3389/fphar.2025.1532123.
2. Dziedziak M, Mytych A, Szyller HP, Lasocka M, Augustynowicz G, Szydziak J, Hrapkowicz A, Dyda M, Braksator J, Pytrus T. Gut Microbiota in Psychiatric and Neurological Disorders: Current Insights and Therapeutic Implications. Biomedicines. 2025; 13(9):2104. https://doi.org/10.3390/biomedicines13092104
3. Hou, K., Wu, ZX., Chen, XY. et al. Microbiota in health and diseases. Sig Transduct Target Ther 7, 135 (2022). https://doi.org/10.1038/s41392-022-00974-4
4. Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.
5. Chojnacki, C.; Konrad, P.; Błońska, A.; Medrek-Socha, M.; Przybylowska-Sygut, K.; Chojnacki, J.; Poplawski, T. Altered Tryptophan Metabolism on the Kynurenine Pathway in Depressive Patients with Small Intestinal Bacterial Overgrowth. Nutrients 2022, 14, 3217.
6. Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761
7. Socała K., Doboszewska U., Szopa A., Serefko A., Włodarczyk M., Zielińska A., Poleszak E., Fichna J., Wlaź P. The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders. Pharmacol. Res. 2021;172:105840. doi: 10.1016/j.phrs.2021.105840.
8. Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670
9. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01

10. Góralczyk-Bińkowska, A.; Szmajda-Krygier, D.; Kozłowska, E. The Microbiota–Gut–Brain Axis in Psychiatric Disorders. Int. J. Mol. Sci. 2022, 23, 11245.
11. Heiss C.N., Olofsson L.E. The Role of the Gut Microbiota in Development, Function and Disorders of the Central Nervous System and the Enteric Nervous System. J. Neuroendocrinol. 2019;31:e12684. doi: 10.1111/jne.12684.
12. Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07
13. Angst D., Gessier F., Janser P., Vulpetti A., Wälchli R., Beerli C., et al. Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton's Tyrosine Kinase. J. Med. Chem. 2020;63(10):5102–5118. doi: 10.1021/acs.jmedchem.9b01916.
14. Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06
15. Guerra E., Garcia-Sanchez Y., Jornet-Gibert M., Nuñez J., Balaguer-Castro M., Madden K. Clinical practice guidelines: The good, the bad, and the ugly. Injury. 2022;54((Suppl. S3)):S26–S29. doi: 10.1016/j.injury.2022.01.047.
16. Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863
17. Asahina Y., Wurtz N.R., Arakawa K., Carson N., Fujii K., Fukuchi K., et al. Discovery of BMS-986235/LAR-1219: a potent formyl peptide receptor 2 (FPR2) selective agonist for the prevention of heart failure. J. Med. Chem. 2020;63(17):9003–9019. doi: 10.1021/acs.jmedchem.9b02101.
18. Sanoev Z.I., Abdinazarov I.T., Rakhimboev S.D., Rashidov S.Z., Hamroyev T.T. Study Of The General Pharmacological Properties Of A New Antiarrhythmic N-Deacetyllappaconitine With Oral Administration. The American Journal of Medical Sciences and Pharmaceutical Research, 3(03), 60-64. https://doi.org/10.37547/TAJMSPR/Volume03Issue03-08
19. Patton E.E., Zon L.I., Langenau D.M. Zebrafish disease models in drug discovery: From preclinical modelling to clinical trials. Nat. Rev. Drug Discov. 2021;20:611–628. doi: 10.1038/s41573-021-00210-8.
20. Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820
21. Stokes, J.M.; Yang, K.; Swanson, K.; Jin, W.; Cubillos-Ruiz, A.; Donghia, N.M.; MacNair, C.R.; French, S.; Carfrae, L.A.; Bloom-Ackermann, Z. A deep learning approach to antibiotic discovery. Cell 2020, 180, 688–702.e613.
22. Sanoev, Z.I., Djaxangirov, F.N., Sadikov, A.Z., Sagdullaev, S.S. Hamroyev T.T. Antiarrhythmic activity of N-deacetyllappaconitine when administered orally. Annals of the Romanian Society for Cell Biology,2021,25(2), 2339–2346. https://doi.org/10.37547/tajas/Volume03Issue03-06

23. Thafar, M.A.; Alshahrani, M.; Albaradei, S.; Gojobori, T.; Essack, M.; Gao, X. Affinity2Vec: Drug-target binding affinity prediction through representation learning, graph mining, and machine learning. Sci. Rep. 2022, 12, 4751.
24. Sokhib Rashidov Zamon o‘g‘li, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o‘g‘li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856
25. Frileux, S.; Boltri, M.; Doré, J.; Leboyer, M.; Roux, P. Cognition and Gut Microbiota in Schizophrenia Spectrum and Mood Disorders: A Systematic Review. Neurosci. Biobehav. Rev. 2024, 162, 105722.
26. Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434
27. Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN : 2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577
28. Kong Y.K., Song K.-S., Jung M.E., Kang M., Kim H.J., Kim M.J. Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett. 2022;56 doi: 10.1016/j.bmcl.2021.128466.
29. Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.
30. Sokhib Rashidov Zamon o‘g‘li, Nilufar Ergasheva Ag’zamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065
31. Günther J., Hillig R.C., Zimmermann K., Kaulfuss S., Lemos C., Nguyen D., et al. BAY-069, a Novel (Trifluoromethyl) pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe. J. Med. Chem. 2022;65(21):14366–14390. doi: 10.1021/acs.jmedchem.2c00441.
32. Sokhib Rashidov Zamon o‘g‘li, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Po‘latjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

33. Rosa J.G.S., Lima C., Lopes-Ferreira M. Zebrafish larvae behavior models as a tool for drug screenings and pre-clinical trials: A review. Int. J. Mol. Sci. 2022;23:6647. doi: 10.3390/ijms23126647.
34. Sokhib Rashidov Zamon o‘g‘li, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania. Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142
35. Sokhib Rashidov Zamon o‘g‘li, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.
36. Cockerill G.S., Angell R.M., Bedernjak A., Chuckowree I., Fraser I., Gascon-Simorte J., et al. Discovery of sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion. J. Med. Chem. 2021;64(7):3658–3676. doi: 10.1021/acs.jmedchem.0c01882.
37. Sokhib Rashidov Zamon o‘g‘li, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qo‘shbekova Ro‘zimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857
38. Yang H, Wang A, Yang J, Luo R and Yang Y (2025) Alterations in gut microbiota composition in neurodevelopmental disorders: a systematic review and meta-analysis. Front. Microbiol. 16:1650212. doi: 10.3389/fmicb.2025.1650212
39. Sapna F, Raveena F, Chandio M, Bai K, Sayyar M, Varrassi G, Khatri M, Kumar S, Mohamad T. Advancements in Heart Failure Management: A Comprehensive Narrative Review of Emerging Therapies. Cureus. 2023 Oct 4;15(10):e46486. doi: 10.7759/cureus.46486.